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Impact of Glutamine Supplemented Total 
Parenteral Nutrition in Surgical patients: 
A systematic review of the evidence
Christina Gavri, MSc
A B S T R A C T
BACKGROUND: The importance of the metabolic role of glutamine has been dem-
onstrated in several laboratory and clinical studies. A number of publications have 
addressed issues relevant to the benefits of the parenteral use of glutamine in patients 
with a variety of conditions.
OBJECTIVE: To review published evidence of the relationship between glutamine 
supplemented total parenteral nutrition (TPN) and infection rates, length of hospital 
stay, nitrogen balance, total lymphocyte count and mortality in patients undergoing 
elective surgery.
MATERIAL AND METHODS: 146 titles, abstracts, and articles were reviewed. Those 
primary studies were included that were randomized trials of surgical patients requir-
ing TPN. The effect of glutamine enriched TPN (Gln-enriched TPN) regimen vs. 
standard TPN regimen on clinical and biological outcomes was evaluated.
RESULTS: Eight randomized trials were found. When the results of these trials were 
analyzed with respect to infection, Gln-enriched TPN was associated with a relative 
risk ratio (RR) of 0.368 (95% CI, 0.162-0.832, p=0.016). Gln-enriched TPN was 
also associated with reduced length of hospital stay (1.191 days less; 95% CI 0.395-
1.986, p=0.004), better cumulative nitrogen balance (2.568gr; 95% CI 1.274-3.863, 
p=0.000), an increase in total lymphocyte count (2.246 /ìL; 95% CI 0.416-4.076, 
p=0.017), and a reduction in mortality rate (RR 0.723; 95% CI 0.174-3.012, p=0.656). 
No side-effects were reported. 
CONCLUSION: There is strong evidence that a benefit from Gln-enriched TPN may 
exist for surgical patients in terms of length of hospital stay, infection rate, total 
lymphocyte count and cumulative nitrogen balance.  The benefit from glutamine-en-
riched TPN on mortality was not found to be statistically significant.
I N T R O D U C T I O N
Glutamine is a five-carbon amino acid with two amino moieties, and accounts 
for 30-35% of all the amino acid nitrogen that is transported in the plasma [1]. It is a 
non-essential amino acid, which occupies a central role in many metabolic pathways. 
It comprises more than 50% of the body’s free amino acid pool and is a precursor that 
donates nitrogen (N) for the synthesis of nucleic acids, purines, pyrimidines, amino 
sugars and glutathione. It is also the most important substrate for renal ammoniagen-
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esis. Glutamine is considered as a nitrogen “shuttle” between 
tissues and as a fuel for enterocytes, colonocytes, lymphocytes 
and proliferating cells [2,3]. It is also often considered to be 
of prime importance for immunomodulation [4]. Numerous 
studies in patients and animals have demonstrated that glu-
tamine feeding increases immune function and can result in 
better nitrogen homoeostasis [5].
Although glutamine is not an essential amino acid, 
glutamine deficiency with its severe complications that com-
monly occur during periods of metabolic stress, has led to 
the reclassification of glutamine as a conditionally essential 
amino acid [6-8].
In hypercatabolic conditions, even though glutamine can 
be readily synthesized de novo within many tissues, the de-
mand may exceed the body’s capacity to synthesize it. There 
is enough evidence that hypercatabolic and hypermetabolic 
situations are accompanied by marked reduction in blood 
and skeletal muscle intracellular glutamine. The intracel-
lular concentration of glutamine may decline by more than 
50% and the plasma level may fall by up to 30% [6,7]. This 
has been observed after elective operations, surgical trauma, 
major injury, burns, infections and pancreatitis, irrespectively 
of nutritional efforts at its repletion. Tissue and plasma glu-
tamine remains reduced up to 7 days after surgery. It also 
appears that the magnitude of reduction is unrelated to the 
severity of trauma [9,10].
The etiology of the fall of muscle glutamine is not yet 
known, but the mechanism may well include a loss of the abil-
ity of the glutamine transporter to maintain a concentration 
gradient across the muscle [11].
Moreover, recently published data show that, during a 
critical illness, there is an average loss of lean body mass of 
1% /day extrapolated to a skeletal muscle loss of 2%/day, and 
consequently a loss of muscle glutamine [12]. The decline in 
muscle glutamine is particularly important since 80% of the 
free amino acids of the body reside within the intracellular 
compartment of skeletal muscle, and glutamine accounts for 
approximately two-thirds of these free amino acids [6]. It has 
further been postulated that there is a change in the “set-
ting” of the muscle transport system of glutamine, resulting 
in a lowered plasma/muscle concentration ratio despite an 
increased net flow of glutamine from muscle to plasma. Thus, 
the decrease in muscular glutamine concentration presumably 
reflects a pronounced increase in the clearance of glutamine 
by the liver, kidney, and mostly the gut [11]. It seems that the 
lost glutamine from skeletal muscle and blood is primarily 
used by visceral organs for a variety of purposes [13].
During catabolic states, glutamine is used for renal am-
moniagenesis, but it also serves as “fuel” for stimulated lym-
phocytes, macrophages and intestinal mucosal cells [14].
More specifically, glutamine is the preferred fuel for oxi-
dative metabolism by the enterocytes. Animal studies have 
demonstrated that enterocytes of the gastrointestinal tract use 
glutamine as a respiratory fuel and during critical illness the 
consumption of glutamine by the gut significantly increases 
[15]. A study by McAnena et al (1991) confirmed that, for the 
first time in humans, selective uptake of glutamine occurs in 
the gut of patients with major trauma. During critical illness, 
intestinal consumption of glutamine seems particularly im-
portant, since normal intestine protects the host from intralu-
minal bacteria and their toxins, and disruption in the bowel’s 
barrier function may result in a chronic hypermetabolic state 
and contribute to multi-organ failure [16].
Moreover, lymphocytes require glutamine in order to 
proliferate in response to antigenic challenge. Macrophages 
may consume glutamine as a source of energy and as a pre-
cursor for nucleotides [5]. Rohde et al (1996), in their in vitro 
study, concluded that glutamine influences the production of 
some T-cell-derived cytokines, and is, thereby, important for 
optimal lymphocyte proliferation [17]. Heberer et al (1996) 
evaluated the dependence of human lymphocyte functions 
on the exogenous provision of glutamine in a series of in 
vitro experiments. They found that later events of lympho-
cyte activation including cytokine production, proliferation 
of lymphocytes and lymphokine-activated killer cell activity 
depends on exogenous glutamine provision [18].
Furthermore, renal glutamine consumption becomes ap-
preciable during acidosis, when additional circulating gluta-
mine is needed to support renal ammoniagenesis (regulation 
of the acid-base balance) [5].
Glutamine depletion might lead to severe complications, 
such as infections, poor wound healing, impaired immunity, 
increased intestinal permeability, and, finally, multiple organ 
failure [1,13]. Thus, glutamine replacement seems necessary. 
The striking direct correlation between free muscle glutamine 
concentration and the rate of protein synthesis suggests that 
maintenance of the intracellular glutamine pool may promote 
conservation of muscle protein during catabolic stress [19].
Thus, there is an obvious indication for use of glutamine 
supplements in the parenteral nutrition regimen of hypercata-
bolic patients. Glutamine supplements might be beneficial in 
the treatment of stressed and malnourished patients [8]. A 
number of publications have addressed issues relevant to the 
parenteral use of glutamine in a variety of patients. However, 
the routine inclusion of glutamine in parenteral nutrition was 
delayed until 1995 due to concerns about its spontaneous deg-
radation, which results in the formation of pyroglutamic acid 
and ammonia [20].
When this problem was solved, concerns were raised 
about the beneficial role of glutamine used in routine clinical 
practice. A number of questions were posed such as: “Does 
glutamine affect the clinical outcome?”, “Is parenteral glu-
tamine beneficial to a wide range of patients or should it be 
confined to a specific category of patients?”, “What is the 
optimal dose?”.
The objective of the present review is to examine the ef-
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fect of parenteral glutamine supplementation on certain nu-
tritional, clinical and biological endpoints in surgical patients. 
Specifically, the relationship between parenteral glutamine 
supplementation and specific outcomes such as hospital length 
of stay, infection rates, mortality, total lymphocyte count, 
mortality and N balance is examined in patients undergoing 
elective surgery.
M A T E R I A L  A N D  M E T H O D S
Computerized searches were performed looking for 
relevant articles on MEDLINE (1966-2005), PUBMED 
(1990-2005), CINAHL and MEDLINE (In-Process, Other 
Non-Indexed Citations). The text words used were parenteral 
nutrition and glutamine and surgery limiting references to hu-
man studies. The main manufacturers of glutamine products 
were contacted for additional published and unpublished 
studies.
Primary studies were retrieved and selected in this review 
if they met the following criteria:
1. Research design: randomized clinical trial
2. Population: elective surgery, adult subjects who fulfilled all 
the criteria for receiving total parenteral nutrition (TPN) 
before and/or after surgery.
3. Intervention: glutamine enriched TPN (Gln-enriched 
TPN) versus standard care in the post-operative period 
or even one day pre-operatively. Patients did not receive 
any other form of nutritional support at the time of the 
study. TPN with glutamine was compared with an isoca-
loric, isonitrogenous TPN formulae with no glutamine 
(standard practice). Basic selection criteria was that both 
intervention and standard TPN regimen contained all 
three macronutrients (fat, carbohydrates, protein) in the 
same proportions, in both study and control groups. Stud-
ies with both peripheral and central TPN were included.
4. Outcomes: hospital length of stay, infection rate, mortality, 
total lymphocyte count and cumulative N balance.
Studies evaluating the impact of Gln-enriched-TPN on 
other biological or mechanistic endpoints were excluded.
Immunonutrition interventions in studies in which glu-
tamine was one of several nutrients given together (e.g. with 
arginine and omega-3 fatty acids) were not included. Studies 
evaluating the effects of glutamine keto-analogues or metabo-
lites (namely glutamate) were also not included. Because of 
issues of clinical heterogeneity, studies of pediatric, or neona-
tal patients, or studies referring to adults undergoing chemo-
therapy, and bone-marrow transplantation were excluded.
A N A LY S I S  O F  D A T A  A N D  S T A T I S T I C S
The methodological quality of all selected studies was 
assessed using a scoring system [21-23] presented in Table 
1. An effort was made to contact the authors of the included 
studies and to request further information not contained in 
the published articles.
The outcomes of primary interest were length of hospital 
stay, infection rate, total lymphocyte count and cumulative 
N balance. Relative Risks (RR) and associated confidence 
intervals (CIs) were estimated for all these parameters. Het-
erogeneity across trials was examined. A random effects model 
was used to estimate the overall relative risks regardless of 
whether there is evidence of homogeneity or heterogeneity 
across trials. A sensitivity analysis was performed. In interpret-
ing subgroup differences a p value of p<0.05 was considered 
statistically significant.
R E S U L T S
A total of 146 titles, abstracts and articles were identi-
fied. Initial eligibility screening resulted in 26 original articles 
describing randomized trials of parenteral glutamine supple-
mentation in surgical patients, which were selected for further 
evaluation. Of these potentially eligible studies, 12 met all 
the inclusion criteria. There were two duplicate studies with 
different data analyses and measured outcomes which were 
both included. Three studies did not contain sufficient data 
for their results to be incorporated into the meta-analysis and 
were excluded. Reasons for excluding relevant randomized 
studies included duplicate publications, and insufficient data 
for analysis.
Eligible studies included surgical patients undergoing 
elective resection of carcinoma of the colon or rectum, gas-
tric cancer patients, patients with biliary diseases, patients 
undergoing elective open cholecystectomy, patients with 
secondary peritonitis, abdominal-thoracic surgery patients 
with pancreatic carcinoma, adenocarcinoma of the duode-
num and hepatoma undergoing surgery. The details of each 
individual study, including the methodological quality score 
are described in table 1.
When the results of these trials, involving 291 analyzable 
patients (the study population of the two duplicate studies were 
considered only once), were aggregated with respect to infec-
tion, Gln-enriched TPN was associated with an RR of 0.368 
(95% CI 0.162-0.832, p=0.016). The test for heterogeneity 
was not significant (p=0.893). There was, therefore, a signifi-
cant reduction in the infectious complication rate in surgical 
patients who received Gln-enriched TPN as reported in four 
studies, and in a total of 166 study patients (Figure 1).
Six studies reported length of hospital stay in 231 analyz-
able patients. Overall, TPN with glutamine supplementation 
was associated with a significantly shorter hospital stay (1.191 
days less; 95% CI 0.395-1.986, p=0.004). The test for hetero-
geneity was significant (p<0.05) (Figure 2).
Four studies reported cumulative N balance on the fifth 
postoperative day in 110 patients. Overall, Gln-enriched TPN 
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FIGURE 2. Meta-analysis of randomised trials testing the favourable effect of parenteral glutamine in length of hospital stay (Het-
erogeneicity test: p <0.05; random effect model: Difference in means = -1.191 with 95% CI: -1.986, -0.395 and p <0.05).
FIGURE 1. Meta-analysis of randomised trials testing the favourable effect of parenteral glutamine in infection (Heterogeneicity 
tet: p = 0.893; random effect model: RR = 0.368 with 95% CI: 0.162-0.832 and p <0.05).
was associated with a better cumulative N balance (2.568gr; 
95% CI 1.274-3.863, p=<0.05). The test for heterogeneity was 
significant (p<0.05) (Figure 3).
Three studies referring to total lymphocyte count on the 
sixth postoperative day in a total of 109 patients, demonstrated 
that Gln-enriched TPN was associated with a significant in-
crease in total lymphocyte count (2.246 /ìL; 95% CI 0.416-
4.076, p=0.017). The test for heterogeneity was significant 
(p<0.05) (Figure 4).
Mortality was studied in three trials. Gln-enriched TPN 
was associated with a non-significant reduction in mortality 
rate (RR 0.723; 95% CI 0.174-3.012, p=0.656). The test for 
heterogeneity was not significant (p=0.983) (Figure 5).
Two studies referred to side-effects and reported no 
adverse-effects attributable to the Gln-enriched TPN regi-
men.
Due to concerns of clinical heterogeneity, and since sta-
tistical heterogeneity was present in most of the results, we 
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divided the analysed studies in two groups: those with a meth-
odological quality score of ≥8 and those with a methodological 
score of <8. Trials with a higher methodological score demon-
strated a significant association between Gln-enriched TPN 
and reduced length of hospital stay (1.506 days less; 95% CI 
0.151-2.861, p=0.030), better cumulative N balance (2.038gr; 
95% CI 0.485-3.592 p=0.011) and a trend toward increased 
total lymphocyte counts (3.292/ ìL; 95% CI -0.964 to 7.548 
p=0.127). Trials with lower methodological score also demon-
strated reduced length of hospital stay (0.864 days less; 95% 
FIGURE 3. Meta-analysis of randomised trials testing the favourable effect of parenteral glutamine in cumulative N balance (Het-
erogeneicity test: p <0.05; random effect model: Difference in means = -2.568 with 95% CI: -3.863, - 1.274 and p <0.05).
FIGURE 4. Meta-analysis of randomised trials testing the favourable effect of parenteral glutamine in total lymphocyte count (Het-
erogeneicity test: p <0.05; random effect model: Difference in means = -2.246 with 95% CI: -4.076, - 0.416 and p <0.05).
CI 0.272-1.457, p=0.005) and better cumulative N balance 
(3.607gr; 95% CI 1.312-5.903, p=0.003) in the patients with the 
glutamine-supplemented regimen. They also demonstrated a 
trend towards reduced rates of infections (RR=0.245; 95% CI 
0.045-1.347, p=0.106). Both subgroups presented significant 
associations between Gln-enriched TPN, better cumulative 
N balance and reduced length of hospital stay. All other as-
sociations were found to be non-significant.
The dose-dependent effect of glutamine supplementation 
was also evaluated. High dose glutamine (≥40g/kg/BW/day) 
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was associated with a reduction in length of hospital stay 
(0.716 days less; 95% CI 0.366-1.067, p<0.05) and increased 
cumulative N balance (1.106gr; 95% CI 0.355-1.857, p=0.004). 
Lower dose glutamine (<40g/kg/BW/day) was associated with 
better cumulative N balance (3.791 gr; 95% CI 2.354-5.227 
p <0.05), a trend towards a reduction in length of hospital 
stay (3.277 days less; 95% CI -0.957 to 7.511 p=0.127), and a 
non-significant increased total lymphocyte count (3.038/ìL; 
95% CI -1.768 to 7.845 p=0.211). Both subgroups showed a 
significantly better cumulative N balance with glutamine. A 
strong association between Gln-enriched TPN and reduced 
hospital stay was found only in the high-dose glutamine 
group.
Subgroup comparisons with respect to any other outcomes 
were not possible due to insufficient number of patients and 
trials.
D I S C U S S I O N
The importance of the metabolic role of glutamine has 
been demonstrated in several laboratory and clinical studies 
[32-34]. In critical illness, the increased demand in glutamine 
for protein synthesis depletes the amino acid pool, thereby 
reducing glutamine levels in plasma and intracellular muscle 
concentration [35]. The stress response to surgery has been 
shown to increase the release of glutamine from the muscle 
pool and to activate de novo synthesis of glutamine, which 
causes insufficient levels of glutamine in tissue and plasma 
[36]. It was found that critically ill patients with low plasma 
glutamine levels had a higher mortality rate than those with 
normal glutamine levels (even when adjusted for Acute 
Physiology and Chronic Health Evaluation II score) [23]. 
Consequently, in surgical patients, the administration of Gln-
enriched TPN might have beneficial effects [37], by correcting 
the deficit in conventional amino acid solutions.
There are several randomized clinical trials evaluating 
the effect of Gln-enriched TPN in seriously ill patients. In-
dividually the majority of theses studies are underpowered 
to evaluate an effect on clinically important end points. In 
the present meta-analysis the role of Gln-enriched TPN was 
specifically evaluated in the seriously ill surgical patients. An 
attempt was made to combine results of similar studies in order 
to determine a more precise estimate of treatment effect.
In the aggregated estimates, there was no adverse effect 
associated with Gln-enriched TPN. Overall, Gln-enriched 
TPN regimens were associated with a strong trend toward 
a reduction in infections, a shorter hospital stay, a better N 
balance, and an increased total lymphocyte count. There was 
no significant association with mortality.
Because of the small number of studies and the few clini-
cal end points examined, the findings should be considered 
as hypothesis-generating rather than solid indications for the 
routine use of glutamine supplemented TPN. Only three 
studies examined mortality, and only four infectious com-
plications rate.
Recent multi-centre trials and meta-analysis on systemic 
glutamine delivery in a number of seriously ill patients support 
these results. In a French multi-centre randomized control 
trial, one hundred and fourteen ICU patients demonstrated a 
significant reduction in frequency of infections, and pneumo-
nias [38]. Glyceamic control was improved with significantly 
less hyperglycaemia (20 vs 30 p<0.05). Another study, in 
Germany, including 144 ICU patients showed that in those 
patients receiving Gln-enriched TPN for more than nine days, 
the survival rate at six months was significantly better (22/33 vs 
FIGURE 5. Meta-analysis of randomised trials testing the effect of parenteral glutamine in mortality, Results are not statistically 
significant (RR = 0.723 with 95% CI: 0.174, 3.012 and p >0.05).
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13/35 p<0.05) [39]. A recent meta-analysis strongly supports 
the hypothesis that parenteral glutamine has an advantageous 
effect on reducing mortality (RR 0.71; 95% CI 0.51-0.99) [23]. 
The meta-analysis also found that glutamine via the enteral 
route failed to show any effect on mortality (RR 1.08; 95% CI 
0.57-2.01), but glutamine supplementation overall is associ-
ated with lower rates of infection (RR 0.81; 95% CI 0.64-1.0) 
and shorter hospital stay (in the post-operative studies) (-2.6 
days; 95% CI -4.5 to -0.7 days). Current recommendations are 
that parenteral nutrition when used in ICU patients should 
contain glutamine[40].
We hypothesised that the treatment effect of Gln-en-
riched TPN may vary on several factors such as the patient 
population, dose, primary disease and severity of the disease, 
TPN regimen, nutritional status, age of the patients and the 
methodological quality of the individual studies. However, 
the small size and the heterogeneity of the analysed studies 
do not permit firm conclusions.
The impact of various factors on treatment outcome with 
Gln-enriched TPN has to be considered in surgical patients. 
The optimal dose of Gln-enriched TPN in surgical patients 
deserves further investigation. Human studies suggest that 
glutamine supplementation up to 0.5gr/kg/day is safe. A 
meta-analysis by Novak et al on the use of to glutamine in 
patients with serious illness suggests that a dose higher than 
0.2gr/kg/day has greater effect than a lower dose [23]. Accord-
ing to Jackson, the demands in glutamine are high since, in 
ICU patients, administration of 28 g/day produced only mod-
est correction of plasma levels [41]. Dosing studies show that 
between 20-40g intravenous glutamine per day are necessary 
to restore plasma glutamine levels to normal [42].
Other issues than dosage, such as the length of Gln-en-
riched TPN administration and the disease severity, need 
further investigation.
In a randomized controlled trial, ICU patients receiv-
ing Gln-enriched TPN were divided into two subgroups 
according to length of nutritional support. It is noteworthy 
that patients receiving short-term (<5 days) total parenteral 
nutrition demonstrated no benefit with the addition of gluta-
mine. In contrast, patients receiving Gln-enriched TPN for 5 
or more days had fewer catheter infections and a decreased 
6-months mortality rate (P<0.05). Outcome analysis showed 
that, among the various possible outcome determinants, only 
glutamine was associated with clinical benefit [43].
Furthermore, Lin et al explored the relationship of disease 
severity and Gln-enriched TPN. They found that Gln-enriched 
TPN had a beneficial effect on decreasing systemic IL-6 pro-
duction after surgery in patients with less severe illness at 
admission, and that low plasma IL-6 may improve N balance 
in patients undergoing abdominal surgery [28].
C O N C L U S I O N S
On the basis of the findings of our systematic review, we 
conclude that there exists strong evidence for a beneficial 
effect of Gln-enriched TPN in surgical patients in terms of 
length of hospital stay, infections rate, total lymphocyte count 
and cumulative N balance. The benefit on mortality was not 
statistically significant. We consider the results of our meta-
analysis as hypothesis-generating and not as definite proof. 
Nevertheless, since there is no evidence of harm, further 
clinical trials are warranted in order to establish a definitive 
relationship between Gln-enriched TPN and its benefits. The 
specific indications for Gln-enriched TPN and the appropriate 
protocol of administration need to be defined.
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